Christine Chung L.
Corporate Officer/Principal at FIBROGEN, INC.
Net worth: 482 580 $ as of 31/03/2024
Profile
Christine Chung L. is currently the Chairman & Manager at Beijing Falikang Pharmaceutical Co. Ltd., Managing Director at FibroGen (China) Medical Technology Development Co. Ltd., Director at FibroGen International (Cayman) Ltd., Director at FibroGen International (Hong Kong) Ltd., and Senior Vice President-China Operations at FibroGen, Inc. She previously worked as Vice President-Business Development at eMed Technologies Corp.
Chung L.
received her undergraduate degree from Harvard University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
FIBROGEN, INC.
0.21% | 31/03/2024 | 205,353 ( 0.21% ) | 482 580 $ | 31/03/2024 |
Christine Chung L. active positions
| Companies | Position | Start |
|---|---|---|
| FIBROGEN, INC. | Corporate Officer/Principal | 01/01/2007 |
FibroGen (China) Medical Technology Development Co. Ltd.
 FibroGen (China) Medical Technology Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd. is a biomedical technology company based in Beijing, China. FibroGen () is dedicated to developing new mechanisms of action or "best-in-class" innovative drugs and medical devices to meet the unmet clinical needs of Chinese patients. The Chinese company also provides a platform to report adverse events related to FibroGen roxadustat products. The private company was founded in 2011. Christine Chung L. has been the CEO of the company since 2019. | Chief Executive Officer | 01/01/2019 |
Beijing Falikang Pharmaceutical Co. Ltd.
 Beijing Falikang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., Beijing Falikang Pharmaceutical Co. Ltd. is a pharmaceutical company that manufactures pharmaceutical products. Beijing Falikang Pharmaceutical Co. Ltd. is based in Beijing, China. Beijing Falikang Pharmaceutical Co. was acquired by FibroGen (China) Medical Technology Development Co. Ltd. on July 31, 2020 for $2.14 million. The Chinese company was founded in 2019. | Chairman | 27/09/2020 |
| FibroGen International (Hong Kong) Ltd. | Director/Board Member | 01/01/2018 |
| FibroGen International (Cayman) Ltd. | Director/Board Member | 01/01/2019 |
Former positions of Christine Chung L.
| Companies | Position | End |
|---|---|---|
eMed Technologies Corp.
 eMed Technologies Corp. Packaged SoftwareTechnology Services eMed Technologies Corp. developed medical software technologies. It combined PACS, image management, web-based results distribution and web communications into a solution that empowered radiologists to manage more procedures, improve service and gain a competitive edge. It was headquartered in Burlington, MA. | Corporate Officer/Principal | - |
Training of Christine Chung L.
| Harvard University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| Private companies | 5 |
|---|---|
eMed Technologies Corp.
eMed Technologies Corp. Packaged SoftwareTechnology Services eMed Technologies Corp. developed medical software technologies. It combined PACS, image management, web-based results distribution and web communications into a solution that empowered radiologists to manage more procedures, improve service and gain a competitive edge. It was headquartered in Burlington, MA. | Technology Services |
FibroGen (China) Medical Technology Development Co. Ltd.
FibroGen (China) Medical Technology Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd. is a biomedical technology company based in Beijing, China. FibroGen () is dedicated to developing new mechanisms of action or "best-in-class" innovative drugs and medical devices to meet the unmet clinical needs of Chinese patients. The Chinese company also provides a platform to report adverse events related to FibroGen roxadustat products. The private company was founded in 2011. Christine Chung L. has been the CEO of the company since 2019. | Health Technology |
| FibroGen International (Cayman) Ltd. | |
| FibroGen International (Hong Kong) Ltd. | |
Beijing Falikang Pharmaceutical Co. Ltd.
Beijing Falikang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., Beijing Falikang Pharmaceutical Co. Ltd. is a pharmaceutical company that manufactures pharmaceutical products. Beijing Falikang Pharmaceutical Co. Ltd. is based in Beijing, China. Beijing Falikang Pharmaceutical Co. was acquired by FibroGen (China) Medical Technology Development Co. Ltd. on July 31, 2020 for $2.14 million. The Chinese company was founded in 2019. | Health Technology |
- Stock Market
- Insiders
- Christine Chung L.